The workgroup approved 6 measures: (1) Annual cognitive health assessment for patients ≥ 65 years and for patients with neurologic illnesses at any age (2) Cognitive and functional assessment for patients with MCI or memory loss (3) MCI diagnosis disclosed and counseled on treatment options (4) Assessment and treatment of factors contributing to MCI (5) Avoidance of anticholinergic medications for patients with MCI (6) Education provided to care partners of patients with MCI.
I have used Cognivue for over 8 years. This testing allows me to share cognitive assessments of my patients that provide a personalized, easily understood score.Diego Cahn-Hidalgo, MD.
Validity, Reliability, and Psychometric Properties of a Computerized, Cognitive Assessment Test (Cognivue)
Comparison of the Cognivue Quantitative Assessment Tool and SLUMS to Classify the Risk of Cognitive Impairment
Validation, Reliability, and Psychometric Properties of Cognivue, A Quantitative Assessment of Cognitive Impairment
Cognivue, Inc. Initiates Nationwide Clinical Study to Assess Post-COVID-19 Syndrome (Long Haul Syndrome)
ROCHESTER, N.Y., July 8, 2021—Neuroscience company Cognivue, Inc. today announced the initiation of COG-COVID19, an open-label, prospective, two-armed comparison clinical study to assess the impact of COVID-19 on cognitive function. Researchers from…
Sign-up to schedule a Cognivue demo!Click Here